公告显示，今年5月，海创药业自主研发的用于治疗转移性去势抵抗性前列腺癌(mCRPC)的1类新药氘恩 扎鲁胺软胶囊获批上市。截至报告期末共取得药品销售收入1306.88万元。 北京商报讯（记者 丁宁）8月13日晚间，海创药业（688302）发布2025年半年度报告显示，公司上半年 实现的营业收入约为1316.71万元，同比增长11899.08%；对应实现的归属净利润约为-6185.32万元，同 比出现减亏。 ...

海创药业8月13日披露半年报，公司上半年实现营业收入1316.71万元，同比增长11899.08%；归属于上 市公司股东的净利润亏损6185.32万元，上年同期亏损1亿元；基本每股收益-0.62元。 ...

报告期内，公司实现营业收入大幅增长，主要系公司首个1类新药氘恩扎鲁胺软胶囊于5月29日获批上 市，实现药品销售收入1306.88万元，而上年同期营业收入仅为少量材料销售收入。 人民财讯8月13日电，海创药业(688302)8月13日晚间披露2025年半年报，公司上半年实现营业收入 1316.72万元，同比增长11899.08%；归属于上市公司股东的净利润为亏损6185.32万元，上年同期为亏 损1亿元。 ...

Group 1 - The company reported a revenue of 13.1671 million yuan for the first half of 2025, representing a year-on-year increase of 11,899.08% [1] - The net loss attributable to shareholders was 61.8532 million yuan, compared to a net loss of 100 million yuan in the same period last year [1]

格隆汇8月13日丨海创药业(688302.SH)公布2025年半年度报告，报告期实现营业收入1316.71万元，同比 增长0.84%；归属于上市公司股东的净利润-6185.32万元元；基本每股收益-0.62元。报告期内，公司实 现营业收入大幅增长，主要系公司首个1类新药氘恩扎鲁胺软胶囊（项目号：HC-1119）于2025年5月29 日获批上市，实现药品销售收入1,306.88万元，而上年同期营业收入仅为少量材料销售收入。 ...

Core Insights - Adidas reported a 7% year-on-year revenue growth for FY2025H1, reaching €12.105 billion, with a net profit increase of 121% to €798 million [4] - The brand's revenue growth was 14% on a currency-neutral basis, with all regional markets achieving double-digit growth [4] - The company maintains its full-year guidance, expecting high single-digit revenue growth on a currency-neutral basis for FY2025, with double-digit growth for the Adidas brand [4] Market Trends - The domestic market indices showed positive performance, with the Shanghai Composite Index closing at 3,617.60, up 0.96% [3] - The textile and apparel sector experienced a decline of 2.14% this week, underperforming the broader market [5] - Retail sales of sports and entertainment products grew significantly, with a 22.2% year-on-year increase in the first half of 2025 [5] Industry Dynamics - The Chinese gold consumption in the first half of 2025 was 505.205 tons, a decrease of 3.54% year-on-year, with jewelry consumption dropping by 26% [5] - The pharmaceutical industry is seeing advancements in innovative drugs, particularly in obesity treatments with GLP-1 and Amylin therapies showing promising results in clinical trials [8][11] - In the biopharmaceutical sector, ADC drugs for lung cancer are demonstrating significant efficacy, with several products showing improved outcomes in clinical trials [10][12]

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Core Viewpoint - Haichuang Pharmaceutical has shown significant financing activity, indicating potential investor interest and market confidence in the company [1] Financing Activity - Haichuang Pharmaceutical recorded a net financing inflow of 77.53 million RMB last week, ranking 115th in the market [1] - The total financing amount for the week was 210 million RMB, with repayments amounting to 132 million RMB [1] Capital Flow - Over the past 5 days, the main capital inflow into Haichuang Pharmaceutical was 47.83 million RMB, with a price increase of 3.91% [1] - In the last 10 days, the main capital inflow was 58.37 million RMB, with a price increase of 2.27% [1] Company Profile - Haichuang Pharmaceutical Co., Ltd. was established in 2013 and is located in Chengdu, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 990.16 million RMB and a paid-in capital of 690.11 million RMB [1] - The legal representative of the company is Yuanwei Chen [1] Investment and Intellectual Property - Haichuang Pharmaceutical has invested in 2 external companies and participated in 15 bidding projects [1] - The company holds 23 trademark registrations and 71 patents, along with 89 administrative licenses [1]

Group 1 - Pharmaceutical stocks continued to decline in early trading, with companies like Kexing Pharmaceutical and Bioventure dropping over 11% [1] - Other companies such as Aoxiang Pharmaceutical, Shenlian Biological, Anke Biotechnology, Zhongsheng Pharmaceutical, and Haichuang Pharmaceutical experienced declines of over 6% [1]

Core Points - Chengdu Yingchuang Power Venture Capital Co., Ltd. has reduced its stake in Haichuang Pharmaceutical Co., Ltd. from 10.67% to 5.00% through share sales between July 12, 2023, and July 31, 2025 [1][2] - The reduction involved a total of 3,878,669 shares sold via centralized bidding and block trading methods [1] - The change in shareholding does not trigger mandatory tender offer obligations and does not violate any prior commitments made by the shareholder [1] Group 1 - The shareholder, Chengdu Yingchuang Power Venture Capital Co., Ltd., has no concerted actions with other shareholders [1] - The shareholding change was officially communicated to Haichuang Pharmaceutical through a notice regarding the reduction of shares [1] - The company confirms that the information provided by the shareholder is accurate and complete [1][2] Group 2 - The shareholding before the reduction was 1,056.84 million shares, which represented 10.67% of the total shares [1] - After the reduction, the remaining shares held by the shareholder are 495.08 million, equating to 5.00% of the total shares [1] - The company is required to comply with relevant regulations regarding the disclosure of shareholding changes [1]